Eli Lilly & Co
Eli Lilly & Co appears in FDA public data with 5 recalls — including 1 Class I (most serious) —, 7 510(k) clearances, 36 FDA inspections, and 3 compliance actions on record. Its most recent recall (D-0445-2024, Class II) was initiated on Mar 12, 2024. Its most recent 510(k) clearance was granted on Sep 16, 2022.
Summary
- Total Recalls
- 5 (1 Class I)
- 510(k) Clearances
- 7
- Inspections
- 36
- Compliance Actions
- 3
Known Names
Eli Lilly And, Eli Lilly And Company, Eli Lilly And Company India Pvt
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0445-2024 | Class II | Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human in | Mar 12, 2024 |
| D-0009-2022 | Class I | Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Gluca | Sep 24, 2021 |
| D-0773-2021 | Class II | Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box, Rx only, Eli Lilly and Company, | Aug 19, 2021 |
| D-0720-2021 | Class II | Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Li | Jun 29, 2021 |
| D-0248-2019 | Class III | ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactu | Nov 8, 2018 |